Preclinical News and Research

RSS

Novel HIV vaccine set for clinical development

A promising new HIV vaccine created at The Wistar Institute has received funding for clinical development aimed at moving the vaccine into human clinical trials as soon as possible.

3 Sep 2007

The goals of platelet inhibition in acute coronary syndromes

Platelet activation and aggregation play important roles in the pathogenesis of cardiac ischemic events after either spontaneous plaque disruption in acute coronary syndromes or mechanical disruption of coronary artery plaques caused by percutaneous coronary intervention (PCI), which could be considered an artificially induced acute coronary syndrome.

3 Sep 2007

FDA grants orphan drug designation to TREANDA

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for the company's investigational therapy, TREANDA (bendamustine HCl), for the treatment of chronic lymphocytic leukemia (CLL).

29 Aug 2007

Animal model for dengue research

A mosquito-borne disease often known as "break-bone fever" has found a new enemy in a unique type of mouse.

28 Aug 2007

Pfizer and Bristol-Myers Squibb finalize agreement on metabolic disorders program

Pfizer Inc. and Bristol-Myers Squibb Company have announced that they have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors, a collaboration first announced on April 26, 2007.

28 Aug 2007

New options in treating pigmentation disorders

Melanocytes are not the only cells responsible for differences in skin coloration. New research from the University of Cincinnati (UC) has shown that some of the most basic cells on the skin's surface influence pigment production and help regulate skin coloration.

24 Aug 2007

Rapamycin study is first stage in development of new treatment

Rapamycin isn't your ordinary potential anti-cancer drug…It had a long and somewhat exotic history before undergoing preclinical (laboratory-based) studies at St. Jude as part of a national Pediatric Preclinical Testing Program (PPTP) investigation of its anticancer activity.

23 Aug 2007

Age-related macular degeneration patient receives investigational eye drops

An 88-year-old man at The Methodist Hospital in Houston is one of two patients in the world today to receive an investigational eye drop that may restore sight for those suffering from neovascular (wet) age-related macular degeneration, a major cause of central visual loss and one of the leading causes of blindness in people over 60 in the United States.

17 Aug 2007

Metformin kills some cancer cells

Researchers at the University of Pennsylvania School of Medicine have found that a commonly prescribed diabetes drug kills tumor cells that lack a key regulatory gene called p53.

16 Aug 2007

Oestrogen research points to new class of analgesic drugs

Oestrogen plays an important role in determining how sensitive a person is to pain, and the oestrogen receptor known as ER-beta is particularly significant in this context.

13 Aug 2007

Light-activated molecules used to induce apoptosis in cancer cells

A key challenge facing doctors as they treat patients suffering from cancer or other diseases resulting from genetic mutations is that the drugs at their disposal often don't discriminate between healthy cells and dangerous ones -- think of the brute-force approach of chemotherapy, for instance.

12 Aug 2007

Handheld BrainScope device detects brain damage immediately after concussion

Researchers at NYU School of Medicine have developed a handheld device that can detect subtle brain damage immediately after concussion.

7 Aug 2007

Novavax begins human clinical testing of novel pandemic flu vaccine

Novavax has announced that it has begun vaccinating healthy volunteers in the first human clinical trial of its virus-like particle ("VLP") based pandemic influenza vaccine.

1 Aug 2007

Huntington's disease study shows animal models on target

An international team of researchers has published a benchmark study showing that gene expression in several animal models of Huntington's Disease (HD) closely resembles that of human HD patients.

1 Aug 2007

ZARS starts phase 3 trial of ThermoProfen

ZARS, Inc., has announced that it commenced the first of two Phase 3 clinical trials of ThermoProfen in patients with mild to moderate osteoarthritis (OA) of the knee on June 26, 2007.

26 Jul 2007

Arius begins toxicology program for lead anti-cancer antibody

ARIUS Research Inc has announced that the Company has initiated the first study in the formal pre-clinical toxicology program for its lead anti-CD44 drug candidate, which is under development for the treatment of breast, prostate and liver cancers.

23 Jul 2007

Affiris alzheimer's vaccine in clinical trial

The Alzheimer's vaccine known as Affitope AD01 from Affiris has now entered the clinical phase of its development. All relevant regulatory and statutory approvals have been secured and this innovative treatment is now being tested on humans for the first time.

19 Jul 2007

Suicide gene therapy for cancer

Cutting-edge research at South Dakota State University may yield a new therapy that targets only cancer cells, leaving healthy cells unharmed.

18 Jul 2007

Vegetable, fruit and fiber rich - low fat diet, does not appear to reduce breast cancer recurrence

Women with early stage breast cancer who adopted a diet very high in vegetables, fruit and fiber and low in fat did not have a lower risk of breast cancer recurrence compared to women who followed a diet of five or more servings a day of fruit and vegetables (the "5-A-Day" diet), according to a study in the July 18 issue of JAMA: The Journal of the American Medical Association.

18 Jul 2007

Researchers identify new combination therapy that promotes cancer cell death

Researchers at the University of Pennsylvania School of Medicine identified a combination therapy as a way to sensitize resistant human cancer cells to a treatment currently being tested in clinical trials They propose that the therapy may help to selectively eliminate cancer cells while leaving healthy cells intact, providing a cancer treatment with fewer side effects.

17 Jul 2007